RK 023

Drug Profile

RK 023

Alternative Names: Nobiprostolan; RK-023

Latest Information Update: 09 Dec 2015

Price : $50

At a glance

  • Originator R-Tech Ueno
  • Developer Sucampo Pharmaceuticals
  • Class Fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Male pattern baldness
  • Phase I Hypotrichosis

Most Recent Events

  • 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals
  • 21 Jul 2015 Phase-IIa development is still ongoing for Male pattern baldness in Japan
  • 24 Apr 2012 R-Tech Ueno completes a phase I trial in Healthy volunteers in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top